Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Liposarcoma: early-phase trial registry
8 of 14 indexed Liposarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 8 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Liposarcoma: 14 US clinical trials tracked, 8 recruiting.
Liposarcoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 4 of these trials.
Enrollment posture brief
Registry condition liposarcoma
OPEN 8 | RECR 57% | LATE 1 | EARLY 13 | RANK #1230 | SPON 4
Volume-matched condition peers
Nearest open-share peer: ACL (57% recruiting · 7 trials)
Liposarcoma lists 8 open slots (57% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Liposarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Liposarcoma is recruiting above its size-band peers.
8 of 14 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Liposarcoma research.
Baylor College of Medicine accounts for 4 of 14 trials (28.6%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Liposarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 24 among the 14 trials that report a genuine target (sentinel values excluded). 10 of those (71.4%) plan for fewer than 100 participants.
-
Liposarcoma research is mostly interventional.
14 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT04031677
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
NCT06239272
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
NCT06541262
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT06843967
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
Michael Wagner, MD
NCT06414434
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
NCT04715191
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Baylor College of Medicine
NCT06198296
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Seattle Children's Hospital
NCT07148050
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Pfizer
NCT04557449
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
NCT02923778
Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery
OHSU Knight Cancer Institute
NCT03361436
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Baylor College of Medicine
NCT04377932
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
NCT05103631
Bevacizumab and Radiation Therapy for Sarcomas
Massachusetts General Hospital
NCT00356031
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Liposarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Liposarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Liposarcoma page
14 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Liposarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Liposarcoma trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Liposarcoma condition card totals 14 registered trials; most-linked intervention Surgery; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.